Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free CTKB Stock Alerts

Cytek Biosciences (CTKB) Financials

Cytek Biosciences logo
$4.05 -0.08 (-1.94%)
Closing price 04:00 PM Eastern
Extended Trading
$4.03 -0.02 (-0.49%)
As of 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Cytek Biosciences

Annual Income Statements for Cytek Biosciences

This table shows Cytek Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 2.58 -12 -6.02
Consolidated Net Income / (Loss)		 2.48 -12 -6.02
Net Income / (Loss) Continuing Operations		 2.48 -12 -6.02
Total Pre-Tax Income 		1.26 -16 -5.70
Total Operating Income		 -1.80 -28 -21
Total Gross Profit		 101 109 111
Total Revenue		 164 193 200
Operating Revenue		 164 193 200
Total Cost of Revenue		 63 84 89
Operating Cost of Revenue		 63 84 89
Total Operating Expenses		 103 137 132
Selling, General & Admin Expense		 35 44 43
Marketing Expense		 33 49 49
Research & Development Expense		 35 44 39
Total Other Income / (Expense), net		 3.06 12 15
Interest Expense		 2.57 2.07 -5.24
Interest & Investment Income		 4.62 6.41 5.12
Other Income / (Expense), net		 1.02 7.79 4.46
Income Tax Expense		 -1.22 -3.56 0.32
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.09 0.00 0.00
Weighted Average Basic Shares Outstanding		 134.51M 135.28M 130.61M
Weighted Average Diluted Shares Outstanding		 138.56M 135.28M 130.61M
Weighted Average Basic & Diluted Shares Outstanding		 135.43M 130.82M 128.10M

Quarterly Income Statements for Cytek Biosciences

This table shows Cytek Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 1.67 3.53 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Consolidated Net Income / (Loss)		 1.63 3.72 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Net Income / (Loss) Continuing Operations		 1.63 3.72 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Total Pre-Tax Income 		1.85 4.11 -9.04 -6.60 -4.19 4.11 -8.99 -7.19 0.16 10
Total Operating Income		 1.36 0.08 -12 -9.13 -6.42 -0.14 -11 -8.53 -4.25 2.99
Total Gross Profit		 27 29 21 28 27 33 23 25 29 34
Total Revenue		 40 48 37 50 48 58 45 47 52 57
Operating Revenue		 40 48 37 50 48 58 45 47 52 57
Total Cost of Revenue		 14 19 16 22 21 25 22 21 22 24
Operating Cost of Revenue		 14 19 16 22 21 25 22 21 22 24
Total Operating Expenses		 26 29 33 37 34 33 34 34 33 31
Selling, General & Admin Expense		 8.04 11 12 11 10 11 11 12 11 9.07
Marketing Expense		 8.81 9.03 11 14 12 12 13 12 12 12
Research & Development Expense		 8.65 9.75 9.97 12 11 11 9.80 10 9.88 9.72
Total Other Income / (Expense), net		 0.49 4.03 3.12 2.53 2.24 4.25 1.74 1.34 4.41 7.34
Interest Expense		 0.65 0.69 0.67 0.41 0.60 0.39 0.44 0.13 0.12 -5.93
Interest & Investment Income		 1.58 2.63 2.14 1.20 1.62 1.45 1.36 1.42 1.43 0.91
Other Income / (Expense), net		 -0.45 2.09 1.65 1.74 1.21 3.19 0.82 0.06 3.09 0.49
Income Tax Expense		 0.22 0.40 -2.23 -2.21 2.27 -1.39 -2.82 3.25 -0.78 0.68
Weighted Average Basic Shares Outstanding		 134.71M 134.51M 135.49M 135.92M 136.17M 135.28M 130.92M 131.44M 131.00M 130.61M
Weighted Average Diluted Shares Outstanding		 138.71M 138.56M 135.49M 135.92M 136.17M 135.28M 130.92M 131.44M 132.79M 130.61M
Weighted Average Basic & Diluted Shares Outstanding		 134.85M 135.43M 135.67M 136.36M 135.55M 130.82M 131.27M 131.51M 128.81M 128.10M

Annual Cash Flow Statements for Cytek Biosciences

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -65 -132 -69
Net Cash From Operating Activities		 -12 5.28 25
Net Cash From Continuing Operating Activities		 -12 7.48 25
Net Income / (Loss) Continuing Operations		 2.48 -12 -6.02
Consolidated Net Income / (Loss)		 2.48 -12 -6.02
Depreciation Expense		 2.49 6.05 7.21
Amortization Expense		 3.09 - -1.93
Non-Cash Adjustments To Reconcile Net Income		 17 21 18
Changes in Operating Assets and Liabilities, net		 -38 -7.10 8.03
Net Cash From Investing Activities		 -56 -94 -83
Net Cash From Continuing Investing Activities		 -56 -94 -83
Purchase of Property, Plant & Equipment		 -9.75 -4.69 -3.53
Acquisitions		 -0.12 -45 -0.68
Purchase of Investments		 -46 -176 -274
Sale of Property, Plant & Equipment		 0.00 0.00 0.29
Sale and/or Maturity of Investments		 0.00 132 195
Net Cash From Financing Activities		 5.51 -42 -16
Net Cash From Continuing Financing Activities		 5.51 -44 -16
Repayment of Debt		 -0.05 -0.57 -0.56
Repurchase of Common Equity		 0.00 -44 -22
Issuance of Debt		 2.98 0.00 4.18
Other Financing Activities, net		 2.58 1.05 2.17
Effect of Exchange Rate Changes		 -2.49 - 4.53
Cash Income Taxes Paid		 10 5.31 3.83

Quarterly Cash Flow Statements for Cytek Biosciences

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -8.37 -42 -167 -0.85 33 3.38 1.51 8.78 -16 -64
Net Cash From Operating Activities		 -7.50 6.19 2.86 -2.85 -4.24 9.51 3.96 6.20 13 2.00
Net Cash From Continuing Operating Activities		 -7.50 6.19 3.45 -3.44 -4.24 12 3.96 6.20 13 2.00
Net Income / (Loss) Continuing Operations		 1.63 3.72 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Consolidated Net Income / (Loss)		 1.63 3.72 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Depreciation Expense		 0.07 0.76 1.00 1.65 1.77 1.63 1.70 1.81 1.85 1.85
Amortization Expense		 0.70 1.03 - - -0.77 - -0.44 -0.51 -0.29 -0.69
Non-Cash Adjustments To Reconcile Net Income		 5.90 3.14 4.50 7.56 6.49 2.13 7.02 7.23 7.46 -3.62
Changes in Operating Assets and Liabilities, net		 -16 -2.46 4.75 -6.15 -5.27 -0.43 1.85 8.11 3.26 -5.18
Net Cash From Investing Activities		 -1.15 -51 -169 2.79 43 29 -5.75 2.02 -16 -63
Net Cash From Continuing Investing Activities		 -1.15 -51 -169 2.69 43 29 -5.75 2.02 -16 -63
Purchase of Property, Plant & Equipment		 -1.11 -6.53 -0.64 -1.17 -1.33 -1.54 -0.57 -1.05 -1.01 -0.89
Acquisitions		 -0.04 -0.08 -45 -0.06 -0.06 -0.06 -0.06 -0.15 0.01 -0.48
Purchase of Investments		 - -44 -123 -6.08 -23 -23 -77 -37 -53 -107
Sale of Property, Plant & Equipment		 - - - - - - - - 0.02 0.19
Sale and/or Maturity of Investments		 - - 0.00 10 68 54 72 40 38 45
Net Cash From Financing Activities		 0.16 3.85 0.00 0.22 -8.27 -34 1.61 -1.71 -12 -3.64
Net Cash From Continuing Financing Activities		 0.16 3.85 0.00 0.22 -8.27 -36 1.61 -1.71 -12 -3.64
Repayment of Debt		 - -0.05 -0.15 -0.14 -0.14 -0.14 -0.14 -0.14 -0.14 -0.14
Repurchase of Common Equity		 - - - - -8.43 -35 - - -12 -6.99
Issuance of Debt		 - - 0.00 - - - 1.39 -0.00 0.01 2.79
Other Financing Activities, net		 0.16 0.92 0.15 0.37 0.29 0.24 0.36 0.09 0.00 1.71
Effect of Exchange Rate Changes		 0.13 -1.00 - - - - 1.70 2.26 -0.94 1.52
Cash Income Taxes Paid		 2.27 0.46 0.09 0.59 0.13 4.50 0.00 1.06 0.86 1.91

Annual Balance Sheets for Cytek Biosciences

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 519 494 500
Total Current Assets		 454 392 396
Cash & Equivalents		 297 167 99
Restricted Cash		 2.90 0.33 0.03
Short-Term Investments		 45 95 179
Accounts Receivable		 49 56 61
Inventories, net		 48 61 44
Prepaid Expenses		 13 13 14
Plant, Property, & Equipment, net		 14 18 18
Total Noncurrent Assets		 52 84 85
Goodwill		 10 16 17
Intangible Assets		 4.33 23 20
Noncurrent Deferred & Refundable Income Taxes		 20 30 33
Other Noncurrent Operating Assets		 17 14 15
Total Liabilities & Shareholders' Equity		 519 494 500
Total Liabilities		 94 101 104
Total Current Liabilities		 49 56 68
Accounts Payable		 4.81 3.03 5.53
Accrued Expenses		 21 20 21
Current Deferred Revenue		 13 23 25
Other Current Liabilities		 10 10 15
Total Noncurrent Liabilities		 45 45 36
Asset Retirement Reserve & Litigation Obligation		 16 16 9.04
Noncurrent Deferred Revenue		 13 15 16
Other Noncurrent Operating Liabilities		 16 14 11
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 426 393 396
Total Preferred & Common Equity		 426 393 396
Total Common Equity		 426 393 396
Common Stock		 443 424 431
Retained Earnings		 -17 -29 -35
Accumulated Other Comprehensive Income / (Loss)		 -0.70 -1.28 0.02

Quarterly Balance Sheets for Cytek Biosciences

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 499 525 525 519 492 484 491
Total Current Assets		 444 426 425 422 389 384 390
Cash & Equivalents		 342 129 132 164 169 178 162
Restricted Cash		 0.00 2.92 0.00 0.00 0.35 0.03 0.03
Short-Term Investments		 - 170 167 124 101 99 116
Accounts Receivable		 40 43 50 55 50 45 53
Inventories, net		 49 70 66 67 55 50 47
Prepaid Expenses		 13 11 11 12 13 12 13
Plant, Property, & Equipment, net		 7.84 16 16 17 18 18 19
Total Noncurrent Assets		 48 83 85 80 85 82 83
Goodwill		 10 19 19 16 16 16 16
Intangible Assets		 4.49 25 24 24 22 21 20
Noncurrent Deferred & Refundable Income Taxes		 14 23 26 24 33 30 31
Other Noncurrent Operating Assets		 19 16 15 15 14 14 15
Total Liabilities & Shareholders' Equity		 499 525 525 519 492 484 491
Total Liabilities		 83 101 101 104 99 95 106
Total Current Liabilities		 41 57 54 59 56 52 63
Accounts Payable		 5.64 5.28 3.08 4.71 3.73 3.19 5.39
Accrued Expenses		 17 20 20 21 18 15 21
Current Deferred Revenue		 12 18 21 23 23 24 25
Other Current Liabilities		 7.12 13 10 10 11 9.73 11
Total Noncurrent Liabilities		 41 45 47 45 44 42 43
Asset Retirement Reserve & Litigation Obligation		 15 16 16 16 17 17 17
Noncurrent Deferred Revenue		 10 13 16 15 15 14 15
Other Noncurrent Operating Liabilities		 16 16 15 14 12 11 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 417 423 424 416 393 389 385
Total Preferred & Common Equity		 417 423 424 416 393 389 385
Total Common Equity		 417 423 424 416 393 389 385
Common Stock		 438 448 454 452 430 435 430
Retained Earnings		 -21 -24 -28 -35 -35 -46 -45
Accumulated Other Comprehensive Income / (Loss)		 -0.53 -0.59 -1.76 -1.58 -1.55 -0.20 0.10

Annual Metrics And Ratios for Cytek Biosciences

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 28.20% 17.67% 3.85%
EBITDA Growth		 -45.94% -391.97% 23.01%
EBIT Growth		 -110.30% -2,451.02% 19.90%
NOPAT Growth		 -176.19% -448.06% 26.30%
Net Income Growth		 -17.94% -589.05% 50.44%
EPS Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -364.17% 143.18% 380.57%
Free Cash Flow Firm Growth		 -85.09% -54.26% 97.23%
Invested Capital Growth		 99.91% 59.91% -9.57%
Revenue Q/Q Growth		 25.87% 5.41% -0.38%
EBITDA Q/Q Growth		 123.01% 20.47% -13.62%
EBIT Q/Q Growth		 96.90% 4.22% 2.54%
NOPAT Q/Q Growth		 78.56% -0.80% 13.20%
Net Income Q/Q Growth		 203.54% 12.81% 40.74%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 5.74% 169.16% -22.85%
Free Cash Flow Firm Q/Q Growth		 0.00% 4.92% -157.34%
Invested Capital Q/Q Growth		 8.68% 2.21% 9.47%
Profitability Metrics		 - - -
Gross Margin		 61.56% 56.69% 55.43%
EBITDA Margin		 2.92% -7.25% -5.38%
Operating Margin		 -1.10% -14.43% -10.24%
EBIT Margin		 -0.48% -10.39% -8.01%
Profit (Net Income) Margin		 1.51% -6.29% -3.00%
Tax Burden Percent		 197.14% 77.33% 105.61%
Interest Burden Percent		 -160.31% 78.35% 35.49%
Effective Tax Rate		 -97.14% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -5.82% -18.40% -11.58%
ROIC Less NNEP Spread (ROIC-NNEP)		 -7.52% -20.82% -14.67%
Return on Net Nonoperating Assets (RNNOA)		 6.42% 15.44% 10.05%
Return on Equity (ROE)		 0.60% -2.97% -1.53%
Cash Return on Invested Capital (CROIC)		 -72.45% -64.50% -1.52%
Operating Return on Assets (OROA)		 -0.16% -3.96% -3.23%
Return on Assets (ROA)		 0.51% -2.40% -1.21%
Return on Common Equity (ROCE)		 0.60% -2.97% -1.53%
Return on Equity Simple (ROE_SIMPLE)		 0.58% -3.09% -1.52%
Net Operating Profit after Tax (NOPAT)		 -3.56 -19 -14
NOPAT Margin		 -2.17% -10.10% -7.17%
Net Nonoperating Expense Percent (NNEP)		 1.70% 2.42% 3.09%
Return On Investment Capital (ROIC_SIMPLE)		 -0.84% -4.96% -3.63%
Cost of Revenue to Revenue		 38.44% 43.31% 44.57%
SG&A Expenses to Revenue		 21.15% 22.78% 21.51%
R&D to Revenue		 21.25% 22.87% 19.66%
Operating Expenses to Revenue		 62.66% 71.12% 65.67%
Earnings before Interest and Taxes (EBIT)		 -0.79 -20 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4.80 -14 -11
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 3.24 3.15 2.11
Price to Tangible Book Value (P/TBV)		 3.35 3.49 2.33
Price to Revenue (P/Rev)		 8.39 6.40 4.17
Price to Earnings (P/E)		 534.49 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.19% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 12.67 7.47 4.74
Enterprise Value to Revenue (EV/Rev)		 6.30 5.04 2.78
Enterprise Value to EBITDA (EV/EBITDA)		 215.35 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 184.33 21.99
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.85 -0.74 -0.69
Leverage Ratio		 1.18 1.24 1.26
Compound Leverage Factor		 -1.90 0.97 0.45
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 10.00 8.30 5.82
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 9.26 6.97 5.86
Quick Ratio		 7.95 5.66 5.00
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -44 -68 -1.89
Operating Cash Flow to CapEx		 -125.47% 112.65% 784.03%
Free Cash Flow to Firm to Interest Expense		 -17.21 -32.99 0.00
Operating Cash Flow to Interest Expense		 -4.75 2.55 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -8.54 0.29 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.33 0.38 0.40
Accounts Receivable Turnover		 4.17 3.68 3.44
Inventory Turnover		 1.57 1.53 1.71
Fixed Asset Turnover		 16.80 12.03 11.02
Accounts Payable Turnover		 16.09 21.33 20.87
Days Sales Outstanding (DSO)		 87.47 99.08 106.08
Days Inventory Outstanding (DIO)		 232.46 238.05 214.00
Days Payable Outstanding (DPO)		 22.69 17.11 17.49
Cash Conversion Cycle (CCC)		 297.25 320.02 302.60
Capital & Investment Metrics		 - - -
Invested Capital		 81 130 118
Invested Capital Turnover		 2.68 1.82 1.62
Increase / (Decrease) in Invested Capital		 41 49 -12
Enterprise Value (EV)		 1,033 973 558
Market Capitalization		 1,377 1,236 836
Book Value per Share		 $3.16 $2.90 $3.07
Tangible Book Value per Share		 $3.05 $2.61 $2.79
Total Capital		 426 393 396
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -344 -263 -278
Capital Expenditures (CapEx)		 9.75 4.69 3.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 61 73 51
Debt-free Net Working Capital (DFNWC)		 405 336 329
Net Working Capital (NWC)		 405 336 329
Net Nonoperating Expense (NNE)		 -6.04 -7.34 -8.35
Net Nonoperating Obligations (NNO)		 -344 -263 -278
Total Depreciation and Amortization (D&A)		 5.58 6.05 5.28
Debt-free, Cash-free Net Working Capital to Revenue		 37.15% 37.87% 25.39%
Debt-free Net Working Capital to Revenue		 246.88% 173.99% 164.02%
Net Working Capital to Revenue		 246.88% 173.99% 164.02%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 134.51M 135.28M 130.61M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 138.56M 135.28M 130.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 135.43M 130.82M 128.10M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.26 -19 -14
Normalized NOPAT Margin		 -0.77% -10.10% -7.17%
Pre Tax Income Margin		 0.77% -8.14% -2.84%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -0.31 -9.68 0.00
NOPAT to Interest Expense		 -1.38 -9.41 0.00
EBIT Less CapEx to Interest Expense		 -4.09 -11.95 0.00
NOPAT Less CapEx to Interest Expense		 -5.17 -11.68 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -363.44% -358.99%

Quarterly Metrics And Ratios for Cytek Biosciences

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 17.75% 230.57% 5.77% 23.74% 18.59% 20.48% 20.96% -6.19% 7.29% -1.30%
EBITDA Growth		 -37.39% 118.28% -654.08% -1,502.93% -349.94% 18.35% 9.00% -24.97% 109.63% -1.11%
EBIT Growth		 -63.46% 109.73% -284.84% -545.15% -669.62% 40.60% 5.70% -14.63% 77.80% 13.67%
NOPAT Growth		 -39.71% -99.87% -415.99% -924.35% -475.96% -339.81% 11.74% 6.57% -466.55% 1,632.15%
Net Income Growth		 14.51% 419.14% -215.43% -525.07% -497.05% 48.01% 9.37% -137.78% 114.58% 75.21%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -746.34% 13.67% 293.11% 69.81% 43.51% 53.59% 38.45% 317.68% 411.89% -79.01%
Free Cash Flow Firm Growth		 -93.80% 0.00% -82.73% -83.72% -20.36% -20.54% 90.44% 110.63% 90.15% 131.15%
Invested Capital Growth		 183.78% 99.91% 170.49% 104.69% 70.04% 59.91% 0.52% -10.74% -15.57% -9.57%
Revenue Q/Q Growth		 0.79% 19.42% -23.27% 33.99% -3.41% 21.32% -22.97% 3.92% 10.47% 11.60%
EBITDA Q/Q Growth		 312.22% 134.99% -340.01% 39.66% 26.56% 211.27% -284.54% 17.13% 105.66% 1,042.12%
EBIT Q/Q Growth		 179.91% 137.70% -583.22% 29.71% 29.44% 158.67% -424.10% 14.56% 86.34% 400.43%
NOPAT Q/Q Growth		 291.65% -93.65% -11,314.47% 24.95% 29.66% 95.95% -4,027.33% 20.56% -326.56% 110.96%
Net Income Q/Q Growth		 331.62% 128.66% -283.08% 35.54% -47.13% 185.24% -212.10% -69.14% 109.02% 924.65%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 20.51% 182.53% -53.85% -199.72% -48.74% 324.39% -58.40% 56.79% 113.10% -84.90%
Free Cash Flow Firm Q/Q Growth		 -23.44% 14.17% -109.38% 17.19% 19.13% 14.04% 83.39% 192.00% -174.94% 371.97%
Invested Capital Q/Q Growth		 22.46% 8.68% 49.14% 3.12% 1.72% 2.21% -6.25% -8.42% -3.78% 9.47%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 66.36% 60.77% 56.72% 56.67% 56.62% 56.75% 51.30% 54.56% 56.32% 58.55%
EBITDA Margin		 4.17% 8.20% -25.64% -11.55% -8.78% 8.05% -19.29% -15.38% 0.79% 8.07%
Operating Margin		 3.36% 0.17% -32.79% -18.37% -13.38% -0.23% -23.93% -18.29% -8.25% 5.20%
EBIT Margin		 2.26% 4.50% -28.34% -14.87% -10.86% 5.25% -22.09% -18.17% -2.25% 6.05%
Profit (Net Income) Margin		 4.02% 7.69% -18.35% -8.83% -13.45% 9.45% -13.75% -22.38% 1.83% 16.78%
Tax Burden Percent		 87.89% 90.37% 75.30% 66.54% 154.27% 133.86% 68.60% 145.20% 599.36% 93.41%
Interest Burden Percent		 202.19% 189.15% 86.01% 89.28% 80.30% 134.43% 90.74% 84.86% -13.57% 296.95%
Effective Tax Rate		 12.11% 9.63% 0.00% 0.00% 0.00% -33.86% 0.00% 0.00% -499.36% 6.59%
Return on Invested Capital (ROIC)		 7.59% 0.42% -45.79% -24.20% -16.93% -0.57% -27.60% -21.34% -84.60% 7.84%
ROIC Less NNEP Spread (ROIC-NNEP)		 7.47% -0.61% -46.31% -24.82% -16.31% -2.44% -28.07% -19.79% -93.94% 5.30%
Return on Net Nonoperating Assets (RNNOA)		 -6.55% 0.52% 37.03% 19.27% 12.34% 1.81% 19.69% 14.02% 66.36% -3.64%
Return on Equity (ROE)		 1.04% 0.94% -8.76% -4.93% -4.59% 1.24% -7.91% -7.32% -18.25% 4.20%
Cash Return on Invested Capital (CROIC)		 0.00% -72.45% -101.80% -83.61% -70.97% -64.50% -15.69% -3.89% 2.80% -1.52%
Operating Return on Assets (OROA)		 0.62% 1.50% -9.31% -5.13% -3.90% 2.00% -8.73% -7.12% -0.89% 2.44%
Return on Assets (ROA)		 1.10% 2.57% -6.03% -3.05% -4.84% 3.60% -5.43% -8.77% 0.73% 6.77%
Return on Common Equity (ROCE)		 1.04% 0.94% -8.76% -4.93% -4.59% 1.24% -7.91% -7.32% -18.25% 4.20%
Return on Equity Simple (ROE_SIMPLE)		 -0.58% 0.00% -0.51% -1.38% -3.35% 0.00% -2.93% -4.51% -2.64% 0.00%
Net Operating Profit after Tax (NOPAT)		 1.20 0.08 -8.51 -6.39 -4.49 -0.18 -7.51 -5.97 -25 2.79
NOPAT Margin		 2.95% 0.16% -22.95% -12.86% -9.36% -0.31% -16.75% -12.80% -49.44% 4.85%
Net Nonoperating Expense Percent (NNEP)		 0.12% 1.03% 0.51% 0.62% -0.62% 1.87% 0.47% -1.55% 9.33% 2.54%
Return On Investment Capital (ROIC_SIMPLE)		 - 0.02% - - - -0.05% - - - 0.70%
Cost of Revenue to Revenue		 33.64% 39.23% 43.28% 43.33% 43.38% 43.25% 48.70% 45.44% 43.68% 41.45%
SG&A Expenses to Revenue		 19.87% 21.75% 32.57% 21.71% 21.56% 18.47% 25.43% 25.09% 21.25% 15.78%
R&D to Revenue		 21.37% 20.17% 26.89% 24.42% 23.27% 18.67% 21.84% 21.45% 19.19% 16.92%
Operating Expenses to Revenue		 63.00% 60.60% 89.52% 75.04% 70.00% 56.98% 75.23% 72.86% 64.57% 53.35%
Earnings before Interest and Taxes (EBIT)		 0.92 2.18 -11 -7.39 -5.21 3.06 -9.91 -8.47 -1.16 3.48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.69 3.96 -9.51 -5.74 -4.21 4.69 -8.65 -7.17 0.41 4.64
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 4.76 3.24 2.94 2.73 1.81 3.15 2.24 1.88 1.89 2.11
Price to Tangible Book Value (P/TBV)		 4.93 3.35 3.28 3.04 2.01 3.49 2.48 2.08 2.09 2.33
Price to Revenue (P/Rev)		 15.21 8.39 7.49 6.60 4.11 6.40 4.37 3.70 3.62 4.17
Price to Earnings (P/E)		 0.00 534.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 21.87 12.67 7.76 6.86 3.64 7.47 4.97 4.07 4.19 4.74
Enterprise Value to Revenue (EV/Rev)		 12.59 6.30 5.68 4.90 2.54 5.04 3.03 2.30 2.24 2.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 215.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 236.84 184.33 95.20 29.50 13.70 21.99
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 136.73 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.88 -0.85 -0.80 -0.78 -0.76 -0.74 -0.70 -0.71 -0.71 -0.69
Leverage Ratio		 1.16 1.18 1.22 1.22 1.22 1.24 1.25 1.24 1.26 1.26
Compound Leverage Factor		 2.35 2.24 1.05 1.09 0.98 1.67 1.13 1.05 -0.17 3.74
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 15.54 10.01 8.42 7.95 5.41 8.46 6.35 5.69 5.21 5.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 10.70 9.26 7.53 7.93 7.20 6.97 6.99 7.33 6.21 5.86
Quick Ratio		 9.19 7.95 6.05 6.50 5.85 5.66 5.77 6.14 5.26 5.00
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -47 -41 -85 -70 -57 -49 -8.14 7.49 -5.61 15
Operating Cash Flow to CapEx		 -676.04% 94.84% 443.79% -242.76% -318.72% 617.66% 697.88% 589.17% 1,335.45% 284.07%
Free Cash Flow to Firm to Interest Expense		 -72.98 -59.18 -126.49 -172.36 -95.82 -124.38 -18.46 55.90 -47.17 0.00
Operating Cash Flow to Interest Expense		 -11.56 9.01 4.25 -6.97 -7.12 24.14 8.97 46.30 111.10 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -13.27 -0.49 3.29 -9.84 -9.36 20.23 7.69 38.44 102.78 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.27 0.33 0.33 0.35 0.36 0.38 0.40 0.39 0.40 0.40
Accounts Receivable Turnover		 3.77 4.17 4.52 4.06 3.85 3.68 4.30 4.19 3.72 3.44
Inventory Turnover		 1.49 1.57 1.20 1.26 1.33 1.53 1.44 1.54 1.60 1.71
Fixed Asset Turnover		 20.32 16.80 15.06 15.32 14.50 12.03 11.88 11.73 11.20 11.02
Accounts Payable Turnover		 11.93 16.09 11.42 14.27 14.95 21.33 19.85 28.39 17.96 20.87
Days Sales Outstanding (DSO)		 96.75 87.47 80.78 89.83 94.72 99.08 84.90 87.01 97.99 106.08
Days Inventory Outstanding (DIO)		 245.80 232.46 305.42 288.94 274.21 238.05 253.67 237.36 228.71 214.00
Days Payable Outstanding (DPO)		 30.59 22.69 31.97 25.57 24.42 17.11 18.39 12.86 20.32 17.49
Cash Conversion Cycle (CCC)		 311.96 297.25 354.24 353.20 344.51 320.02 320.18 311.52 306.38 302.60
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 75 81 122 125 128 130 122 112 108 118
Invested Capital Turnover		 2.57 2.68 1.99 1.88 1.81 1.82 1.65 1.67 1.71 1.62
Increase / (Decrease) in Invested Capital		 49 41 77 64 53 49 0.63 -13 -20 -12
Enterprise Value (EV)		 1,640 1,033 943 860 465 973 607 455 451 558
Market Capitalization		 1,982 1,377 1,245 1,159 753 1,236 878 733 729 836
Book Value per Share		 $3.09 $3.16 $3.13 $3.13 $3.05 $2.90 $3.00 $2.96 $2.93 $3.07
Tangible Book Value per Share		 $2.99 $3.05 $2.80 $2.81 $2.75 $2.61 $2.71 $2.68 $2.65 $2.79
Total Capital		 417 426 423 424 416 393 393 389 385 396
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -342 -344 -302 -299 -288 -263 -270 -277 -278 -278
Capital Expenditures (CapEx)		 1.11 6.53 0.64 1.17 1.33 1.54 0.57 1.05 0.99 0.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 61 61 67 72 76 73 63 54 50 51
Debt-free Net Working Capital (DFNWC)		 402 405 369 371 364 336 333 332 327 329
Net Working Capital (NWC)		 402 405 369 371 364 336 333 332 327 329
Net Nonoperating Expense (NNE)		 -0.43 -3.64 -1.71 -2.00 1.96 -5.69 -1.34 4.47 -26 -6.85
Net Nonoperating Obligations (NNO)		 -342 -344 -302 -299 -288 -263 -270 -277 -278 -278
Total Depreciation and Amortization (D&A)		 0.77 1.79 1.00 1.65 1.00 1.63 1.26 1.30 1.56 1.16
Debt-free, Cash-free Net Working Capital to Revenue		 46.69% 37.15% 40.46% 41.23% 41.29% 37.87% 31.20% 27.55% 24.64% 25.39%
Debt-free Net Working Capital to Revenue		 308.75% 246.88% 222.27% 211.41% 198.57% 173.99% 165.89% 167.77% 162.71% 164.02%
Net Working Capital to Revenue		 308.75% 246.88% 222.27% 211.41% 198.57% 173.99% 165.89% 167.77% 162.71% 164.02%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 134.71M 134.51M 135.49M 135.92M 136.17M 135.28M 130.92M 131.44M 131.00M 130.61M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 138.71M 138.56M 135.49M 135.92M 136.17M 135.28M 130.92M 131.44M 132.79M 130.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 134.85M 135.43M 135.67M 136.36M 135.55M 130.82M 131.27M 131.51M 128.81M 128.10M
Normalized Net Operating Profit after Tax (NOPAT)		 1.20 0.08 -8.51 -6.39 -4.49 -0.10 -7.51 -5.97 -2.97 2.79
Normalized NOPAT Margin		 2.95% 0.16% -22.95% -12.86% -9.36% -0.16% -16.75% -12.80% -5.77% 4.85%
Pre Tax Income Margin		 4.57% 8.51% -24.37% -13.27% -8.72% 7.06% -20.05% -15.42% 0.30% 17.96%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 1.41 3.17 -15.62 -18.06 -8.76 7.76 -22.47 -63.19 -9.72 0.00
NOPAT to Interest Expense		 1.84 0.11 -12.65 -15.62 -7.55 -0.46 -17.04 -44.54 -213.96 0.00
EBIT Less CapEx to Interest Expense		 -0.30 -6.34 -16.57 -20.93 -11.00 3.85 -23.76 -71.05 -18.04 0.00
NOPAT Less CapEx to Interest Expense		 0.13 -9.39 -13.61 -18.49 -9.79 -4.37 -18.32 -52.40 -222.28 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -363.44% 0.00% -261.11% -485.89% -358.99%

Financials Breakdown Chart

Key Financial Trends

Cytek Biosciences’ latest quarter showed a return to solid profitability, but the balance sheet and cash flow trends suggest investors should still watch liquidity and capital allocation closely. In Q4 2024, revenue rose to $57.5 million from $51.5 million a year earlier, while net income climbed to $9.6 million versus $0.9 million in Q3 2024 and a loss in Q2 2024. That said, operating cash flow was weak at just $2.0 million, and the company used a large amount of cash on investments.

What stands out most is the improvement in earnings quality from mid-2024, but not yet in operating cash generation. Cytek’s revenue has been fairly stable to slightly higher over the past year, but operating margins still swing depending on expense levels, and the company continues to spend heavily on marketing, SG&A, and R&D.

  • Q4 2024 revenue grew year over year to $57.5 million from $51.5 million in Q3 2024 and $48.6 million in Q4 2023, showing continued top-line demand.
  • Net income rebounded sharply in Q4 2024 to $9.6 million, up from $0.9 million in Q3 2024 and a loss of $10.4 million in Q2 2024.
  • Gross profit improved to $33.7 million in Q4 2024, with gross margin around 58.5%, better than the prior-year quarter.
  • Balance sheet remains strong on an absolute basis with $162.3 million in cash and equivalents and $115.5 million in short-term investments at the end of Q3 2024.
  • The company still has a large equity cushion with total common equity of $385.5 million at Q3 2024.
  • Revenue growth has been modest, not explosive, with quarterly revenue generally staying in the high-$40 million to high-$50 million range over the past year.
  • Operating expenses remain elevated, especially marketing, SG&A, and R&D, which keep operating income volatile.
  • Deferred revenue is meaningful, which can support future recognized revenue, but it also indicates customer prepayments that must be fulfilled.
  • Operating cash flow weakened dramatically in Q4 2024 to $2.0 million from $13.2 million in Q3 2024.
  • Cash was reduced by investing activity, including $107.3 million in investment purchases in Q4 2024, which drove net cash from investing activities to a large outflow.

Looking at the trend over the last four years, Cytek has moved from profitability in 2022 to a more uneven 2023 and then back toward stronger earnings in 2024. The biggest swing factor has been operating expenses. In 2023, the company posted multiple quarterly losses, including Q1 and Q2, while Q4 2023 was profitable again. In 2024, Q2 was a loss, Q3 was barely profitable, and Q4 showed a much stronger earnings recovery.

From a cash perspective, Cytek still looks financially flexible, but investors should note that a large cash balance does not automatically mean strong business cash generation. The company had sizable cash and investments on the balance sheet through most of 2024, but quarterly cash flow was often distorted by investment purchases and maturities. That means the quality of operating cash flow will be an important metric to watch going forward.

Bottom line: Cytek Biosciences appears to be stabilizing on the earnings front, with improving revenue and a strong Q4 2024 profit. However, inconsistent operating cash flow and continued heavy spending mean the stock still depends on execution, margin discipline, and sustained demand.

06/10/26 09:12 PM ETAI Generated. May Contain Errors.

Cytek Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cytek Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Cytek Biosciences' net income appears to be on an upward trend, with a most recent value of -$6.02 million in 2024, falling from $2.48 million in 2022. The previous period was -$12.15 million in 2023. See Cytek Biosciences' forecast for analyst expectations on what's next for the company.

Cytek Biosciences' total operating income in 2024 was -$20.52 million, based on the following breakdown:
  • Total Gross Profit: $111.11 million
  • Total Operating Expenses: $131.63 million

Over the last 2 years, Cytek Biosciences' total revenue changed from $164.04 million in 2022 to $200.45 million in 2024, a change of 22.2%.

Cytek Biosciences' total liabilities were at $103.76 million at the end of 2024, a 2.3% increase from 2023, and a 10.5% increase since 2022.

In the past 2 years, Cytek Biosciences' cash and equivalents has ranged from $98.72 million in 2024 to $296.60 million in 2022, and is currently $98.72 million as of their latest financial filing in 2024.

Over the last 2 years, Cytek Biosciences' book value per share changed from 3.16 in 2022 to 3.07 in 2024, a change of -2.6%.


Related Companies

Financial statements for NASDAQ:CTKB last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Important SpaceX PREDICTION
The biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian s...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Live demo of Elon Musk’s AI agent
Jeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...
Brownstone Research | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
He Called NVIDIA at $1.10 – Now He Says, “SELL”
The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...
The Oxford Club | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel